A Network of Cancer Genes with Co-Occurring and Anti-Co-Occurring Mutations by Cui, Qinghua
A Network of Cancer Genes with Co-Occurring and Anti-
Co-Occurring Mutations
Qinghua Cui*
Department of Biomedical Informatics, Peking University Health Science Center, Beijing, China
Abstract
Certain cancer genes contribute to tumorigenesis in a manner of either co-occurring or mutually exclusive (anti-co-
occurring) mutations; however, the global picture of when, where and how these functional interactions occur remains
unclear. This study presents a systems biology approach for this purpose. After applying this method to cancer gene
mutation data generated from large-scale and whole genome sequencing of cancer samples, a network of cancer genes
with co-occurring and anti-co-occurring mutations was constructed. Analysis of this network revealed that genes with co-
occurring mutations prefer direct signaling transductions and that the interaction relations among cancer genes in the
network are related with their functional similarity. It was also revealed that genes with co-occurring mutations tend to have
similar mutation frequencies, whereas genes with anti-co-occurring mutations tend to have different mutation frequencies.
Moreover, genes with more exons tend to have more co-occurring mutations with other genes, and genes having lower
local coherent network structures tend to have higher mutation frequency. The network showed two complementary
modules that have distinct functions and have different roles in tumorigenesis. This study presented a framework for the
analysis of cancer genome sequencing outputs. The presented data and uncovered patterns are helpful for understanding
the contribution of gene mutations to tumorigenesis and valuable in the identification of key biomarkers and drug targets
for cancer.
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Introduction
Cancer arises through accumulated genetic and epigenetic
alternations of somatic cells [1,2,3]. In recent years, numerous
efforts have been made to identify gene mutations in various human
cancers by genome-wide or large-scale sequencing [3,4,5,6,7,8,9].
In fact, these studies have identified thousands of cancer gene
mutations, and certain patterns or rules of cancer gene mutations
have been uncovered through the analysis of these mutation data
[1,2,10,11]. The discovery of mutated genes in human cancers and
thepatterns behindthemutationdatahaveprovidedcriticalinsights
into the mechanisms underlying cancer formation and develop-
ment, and have proven helpful for cancer therapy [3,12]. However,
the rapid increase in cancer gene mutation data suggests a high level
of complexity related to understanding the tumorigenic process [2].
Given this complexity, more novel methods for the analyses of
mutation data are needed for a better understanding of cancer.
Generally, cancer gene mutations do not occur randomly.
Mutations of certain cancer genes tend to co-occur (termed co-
occurring mutation in this work), suggesting that they may
contribute together to tumor formation and development.
However, mutations of some other genes occur in a mutually
exclusive fashion (termed anti-co-occurring mutation in this work)
[8], suggesting that two genes with anti-co-occurring mutation
may have highly similar downstream components. For example,
Ras and Braf show anti-co-occurring mutations. Indeed, activaion
of one member is sufficient for activating the MAPK pathway
[13]. Although some cancer genes with co-occurring and anti-co-
occurring mutations have been revealed, the complexity of human
cancer gene mutations prevents us from gaining a global landscape
of cancer gene co-occurring and anti-co-occurring mutations. For
better understanding these functional interactions among cancer
genes, this study presents a systems biology approach and conducts
a comprehensive analysis of cancer genes with co-occurring
mutations and anti-co-occurring mutations.
Results
Network of co-occurring and anti-co-occurring cancer
gene mutations
A network of cancer genes with co-occurring and anti-co-
occurring mutations (CCA network) was constructed by connect-
ing cancer genes that have significant co-occurrence or anti-co-
occurrence with other genes (see Materials and methods). The
CCA network includes 306 genes and 1,366 links (File S1;
Figure 1). Among the 1,366 links, 1,355 (99.2%) are links of co-
occurring gene mutation and only 11 (0.8%) are links of anti-co-
occurring gene mutation. Thus, in this study, all analyses were
performed for genes with co-occurring mutations unless otherwise
stated or explained. The CCA network includes five network
components. The giant (biggest) network component contains
97.4% (298/306) of the total nodes, suggesting that most of the
genes have potential relationships that contribute to tumorigenesis.
The degrees of nodes in the CCA network show a distribution of
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free network.
Preference of genes with co-occurring mutations for
direct activation signaling transductions
It is believed that cancer genes with co-occurring mutations are
not randomly distributed in the cancer genome. Currently, it
remains unclear how co-occurring mutations occur. As cells need
to respond to various signals, and since cell signaling is critical to
tasks such as cell growth, maintenance of cell survival, prolifer-
ation, differentiation, development, and apoptosis, the dysfunction
of cell signaling from gene mutations can result in cancer[1]. To
address the questions above, the distribution of genes with co-
occurring mutations in human cell signaling pathways and in a
human cellular signaling network was investigated. Co-occurring
mutated genes were first mapped into 183 human signaling
pathways, and 42 pairs of genes with co-occurring mutations were
mapped to the same pathways. A randomization test was then
performed to evaluate whether gene co-occurring mutations prefer
to occur in the same signaling pathway (see Materials and
methods). The results suggest that gene co-occurring mutations
prefer to exist in the same signaling pathway (P=0.002,
randomization test, Figure 2A). This observation further suggests
that mutations of a single gene in one signaling pathway may not
necessarily lethally affect the pathway, and that dysfunctions of
one pathway are often the result of the co-occurrence of mutations
of two or more genes. To determine whether genes with co-
occurring mutations tend to have direct interactions during
cellular signaling, the distribution of cancer genes with co-
occurring mutations in a human cellular signaling network was
investigated. A total of 306 cancer genes were first mapped into
the signaling network, and 107 of these genes were determined to
exist in the signaling network. For pairs of genes with co-occurring
mutations, 7.0% of them had direct interactions in the signaling
network. In comparison, for the pairs of genes that did not have
co-occurring mutations, only 2.8% of them had direct interactions
in the signaling network. This indicates that genes with co-
occurring mutations tend to have direct signaling interactions
(P=0.02, Fisher’s exact test, odds ratio (OR)=2.45). Cells must
use correct signals (i.e. activation or repression) to make right
response to various stimulus [14]. Different signals may lead cells
to different fates [15,16]. It is interesting to reveal which signals
these interacting cancer genes prefer to use. For doing so, the
number of different signals among the interacting cancer gene
Figure 1. Network of cancer genes with co-occurring and anti-co-occurring mutations (CCA network). Each node represents one cancer
gene. Genes connected by gray links represent co-occurring mutations. Genes connected by purple links represent anti-co-occurring mutations. The
CCA network has two modules. Nodes in module one are red and nodes in module two are green.
doi:10.1371/journal.pone.0013180.g001
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activation signals (69.2%), less repression signals (6.8%) and
physical interactions (24.0%) than the average (47.5%, 14.6%, and
37.9% for activation, repression, and physical links, respectively).
The signals used by these cancer genes are strongly unbalanced
(P=4.1610
26, Chi-square test). Moreover, these cancer genes
prefer to use activation signals and avoid using repression signals
(P,2.0610
24, randomization test; Figure 2B). These results
suggest that, in many cases, mutations in a single gene in one
signaling pathway cannot significantly affect cellular signaling, and
that accumulated mutations in the activation signaling interaction
tend to amplify the effects of cancer gene mutations and therefore
have significant influences on the dysfunction of the signaling
pathway. These mutations may therefore contribute more to
cancer formation and development than other mutations.
Network distance of genes in the CCA network correlates
with their expression similarity
The above results suggest that cancer genes with co-occurring
mutations tend to be more functionally related than random gene
pairs. Therefore, genes that are close to each other in the network
may be more functionally related than genes that are far away
from each other. It has been reported that gene expression
similarity has a good correlation with gene functional similari-
ty[17,18,19]. Therefore, the network distance (the length of
shortest path between two nodes in a network) of these cancer
genes is expected to be correlated with their expression similarity.
To confirm this expectation, the author first calculated the
expression similarity of pairs of interacting genes in the CCA
network based on human gene expression data presented by Su et
al. [20] by Pearson’s correlation, which is frequently used to
calculate gene expression similarity (see Materials and meth-
ods). Next, the correlation between the network distance and
expression similarity of genes in the CCA network was analyzed.
As expected, network distance and expression similarity are
negatively correlated (R=20.04, P=6.9610
211, Spearman’s
correlation). Considering that many gene pairs have the same
network distance, which may generate bias in the correlation
analysis, gene pairs were further integrated into groups according
to their network distance, and the average expression similarity for
each group of gene pairs was calculated. As shown in Figure 2C,
the network distance of grouped genes is negatively correlated with
their expression similarity (R=20.89, P=0.03, Spearman’s
correlation). These results indicate that genes with co-occurring
mutations tend to be more functionally related, and vice versa.
Genes with co-occurring mutations tend to have similar
mutation frequencies, whereas genes with anti-co-
occurring mutations tend to have different mutation
frequencies
Mutation frequency varies for different cancer genes and
different cancer types. For example, P53 is mutated in nearly
90% of oesophagus cancer samples but only in 7.5% of kidney
cancer samples. Although a large scale of co-occurring mutated
Figure 2. (A) Significance of cancer genes with co-occurring mutations existing in the same signaling pathways. The red arrow
indicates the real number of cancer gene pairs that exist in the same pathway. The curve is the distribution of the random number of cancer gene
pairs that exist in the same pathway. (B) Distribution of number of activation and repression signals among cancer gene pairs with co-occurring
mutations. The red circle (pointed by a red arrow) indicates the real number of activation signals and repression signals that exist among the cancer
gene pairs in the human signaling network. The heatmap indicates the union distribution of the random number of activation signals and repression
signals that exist among the cancer gene pairs in the human signaling network. (C) Correlation between the distance of cancer genes in the CCA
network and their expression similarity.
doi:10.1371/journal.pone.0013180.g002
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mutation frequency of these genes remain unknown. To address
lack, the absolute difference of mutation frequency (AD) for any
two neighbor genes in the network was calculated. The AD values
for genes with co-occurring mutations, genes with anti-co-
occurring mutations, and random gene pairs were then compared.
Genes with co-occurring mutations were found to have smaller
AD values than genes with anti-co-occurring mutations
(P=3.32610
27, Wilcoxon test, Figure 3A). It was also found that
genes with co-occurring mutations have smaller AD values than
random gene pairs (P=0.002, randomization test, Figure 3B),
whereas genes with anti-co-occurring mutations have greater AD
values than random gene pairs (P,0.0002, randomization test,
Figure 3C).
Network features are associated with gene features
An important characteristic of a node in a network is its
degree[21]. The degree of a node is represented as the number of
links it has. This is a vital metric for measuring the centrality of a
node in a network. However, it remains unknown which genes
tend to have more co-occurring mutations than other genes in the
CCA network. As such, the associations of node degree with node
length, mutation frequency, and number of exons were further
investigated. Analysis results show that degree is not associated
with mutation frequency or gene length but is positively correlated
with the number of exons (R=0.13, P=0.02, Spearman’s
correlation). This suggests that proteins composed of more exons
may have greater functional diversity and, therefore, may
potentially have more physical or biochemical interactions with
other proteins. This further suggests that co-occurrence of
mutations of these proteins with other proteins may often be
necessary for the dysfunction of various pathways that contribute
to tumorigenesis.
The clustering coefficient (CC) is yet another important
characteristic for nodes in networks [21] as it represents the
coherence of local regions in networks. The CCA network has an
average CC of 0.48. This indicates that mutations of multiple
genes are often needed in tumorigenesis. Moreover, the CC of
genes is negatively correlated with their mutation frequency
(R=20.19, P=7.09610
24, Spearman’s correlation) and posi-
tively correlated with their degree (R=0.19, P=6.29610
24,
Spearman’s correlation). Considering that genes with co-occurring
mutations tend to be functionally related, as revealed above, this
result suggests that genes in a densely interacted local network
structure (i.e., genes with many mutual interactions) tend to be
more robust against errors (e.g., mutations) and have smaller
lethality than those in a sparsely interacted local network structure.
Furthermore, both degree and CC increase from extracellular
space to nucleus (median degrees are 3, 6, 6, and 6.5; median CCs
are 0.17, 0.40, 0.44, and 0.45), indicating that downstream cellular
components tend to cooperate more with each other in the cellular
dysfunctions contributing to cancer than upstream cellular
components.
The CCA network shows modular structures
Similar to many other biological networks, the CCA network
also shows modular structures. In a network, a network module
refers to a highly interconnected group of nodes[21]. Nodes
between two network modules are sparsely connected. As shown in
Figure 1, the CCA network clearly has two modules. Previous
studies have revealed that nodes in a network module tend to work
together to achieve a specific function [21,22]. To confirm
Figure 3. Comparison of absolute differences of mutation frequency (AD) among genes with co-occurring mutations, genes with
anti-co-occurring mutations, and random gene pairs. (A) Comparison of AD values for genes with co-occurring mutations (red) and genes
with anti-co-occurring mutations (green). (B) Comparison of median AD values for genes with co-occurring mutations (red arrow) and the
distribution of the median values for 5,000 random groups of genes with co-occurring mutations. (C) Comparison of median AD values for genes with
anti-co-occurring mutations (green arrow) and the distribution of the median AD values for 5,000 random groups of genes with anti-co-occurring
mutations.
doi:10.1371/journal.pone.0013180.g003
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functions, the enriched molecular functions (MFs), biological
processes (BPs), and cellular components (CCs) for genes in the
two modules were identified using the DAVID software [23] and
setting all cancer genes in the two modules as the background
population. DAVID is a popular tool to identify enriched gene sets
(i.e. pathways, gene ontology terms) by evaluating the significance
of enrichment of interested genes in each predefined gene set[23].
We took the gene sets with P values less than or equal to 0.05 as
significant gene sets. The results reveal that the two modules have
distinct enriched gene sets (Figure 4; File S2). In terms of cellular
location, for example, Module One is enriched in the membrane
and nucleus, whereas Module Two is enriched in the intracellular
space. Both modules are enriched with the function of binding but
tend to bind with different molecules. Module One is enriched
with DNA binding, whereas Module Two is enriched with binding
small molecules such as adenyl ribonucleotide, purine nucleotide,
ATP, and lipids. Moreover, the two modules are also different in
their metabolic and signaling processes. These results indicate that
genes with co-occurring and anti-co-occurring mutations show
specific architecture with regard to both topology and function.
The author asked if the genes in two modules could operate in a
compensatory or concerted manner to govern various functions.
Toward this end, an independent dataset of whole-genome cancer
gene mutations of 22 cancer samples from Sjoblom et al. ’ study [7]
was used to investigate the distribution of gene mutations in the two
modules. The author counted the numbers of samples that have
gene mutations in both modules, only in Module One, and only in
Module Two, respectively. As a result, among the total 22 cancer
samples, 8 samples have gene mutations in both modules, 14
samples have gene mutations only in Module One, and no samples
have gene mutationsonlyinModuleTwo.Randommodelingofthe
distribution of the three numbers shows that samples have gene
mutations in both modules occur with a chance of 25% in random
case. This result suggests that genes from the two modules have a
tendency to work together in a complementary way to generate
tumor phenotypes. Moreover, all samples have at least one gene
mutation in Module One. This number is significantly greater than
the random case (P,2.0610
24, randomization test; Figure 5A),
indicating that this module seems to be the critical and essential
player in tumorigenesis. This finding is further supported by the
following observations. (a) Module One is enriched in function of
anti-oncogene (File S2). (b) Genes in Module One have higher
fraction of methylation (10.0%, 21/210) in cancer stem cells than
those in Module Two (1.1%, 1/88). The author obtained the
numbers of methylated genes in these two modules by first mapping
methylatedgenesintogenesinthesetwomodulesand thencounting
the numbers of mapped methylated genes in Module One and
Module Two, respectively. Fisher’s exact test shows that cancer
methylated genes has significantly enriched distribution in Module
One (P=0.006), suggesting that genes in Module One contribute
more to the long-term loss of gene expression and represents the
early stage of tumor formation[1]. (c) The mutation frequency of
genes in Module One is significantly higher than that of genes in
Module Two (P=5.75610
29, Wilcoxon test; Figure 5B). The
statistical significance was obtained using Wilcoxon test to test the
difference between two groups of cancer gene mutation frequency
from Module One and Module Two.
Figure 4. Cellular illustration of the enriched cellular components, molecular functions and biological processes of Module One and
Module Two obtained by DAVID Bioinformatics [23]. Module One (words with red color) is enriched in the membrane and nucleus and
Module Two (words with yellow color) is enriched in the intracellular space. The enriched functions and biological processes of each module are also
plotted in the corresponding locations.
doi:10.1371/journal.pone.0013180.g004
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Although a number of cancer genes contribute to tumorigenesis
in a manner of co-occurring or anti-co-occurring mutations, it has
been challenging to gain a global landscape of when, where, and
how their interactions exert affects on tumor formation and
development. By building a CCA network and performing an
integrative analysis of this network, the author uncovered a global
picture of cancer gene co-occurring and anti-co-occurring
mutations. Co-occurring mutations preferentially occur in func-
tionally related gene pairs, such as signaling transduction
molecules, especially the activation signaling transduction mole-
cules. The cancer gene interacting pairs have an affect on their
mutation frequencies. Genes with co-occurring mutations tend to
have similar mutation frequencies, whereas genes with anti-co-
occurring mutations tend to have different mutation frequencies.
Topologically, the CCA network shows two modules that have
specific functions. The two modules tend to have functional
collaborations and Module One seems to be the central player in
contributing to tumorigenesis.
Because of the tremendous diversity and complexity of cancer
gene mutations, cancers even the same type of cancers show very
different mutation profiles and few common patterns behind these
data have been identified. Therefore, some researchers doubt the
value of cancer genomics [24]. By a systems level analysis, this
study has presented direct evidence for the principles of cancer
gene co-occurring and anti-co-occurring mutations, which are
helpful in understanding the mechanism by which cancer genes
contribute to cancer formation and development in a manner of
co-occurring or anti-co-occurring mutations.
The sequencing of cancer genomes is an ongoing process.
Currently, the sequenced mutation data can interpret only a
portion of the mutations. As the development of next generation
genome sequencing technology, more and more cancer gene
mutation data will be accumulated. Therefore, it is expected that
more reliable and novel observations will be realized in the future.
This study presents a systems biology framework for the
integrative analysis of cancer genome sequencing outputs, which
will be useful for not only the understanding of tumorigenesis but
also the identification of valuable biomarkers and drug targets.
Materials and Methods
Cancer gene mutation data
Cancer gene mutation data were downloaded from the
Catalogue of Somatic Mutations in Cancer (December 2008,
COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/).
The mutation frequency of a gene was calculated by dividing the
numberoftotalcancersamples that sequencedthis gene with that of
cancer samples with at least one mutation of this gene, as described
by Cui et al. [1]. Because gene mutation frequency is significantly
correlated with gene length (R=0.4, P=5.16610
214, Spearman’s
correlation), gene mutation frequency wasfurthercorrected by gene
length using formula ‘‘original mutation frequency/gene length’’.
Methylated genes in cancer stem cells
The 287 methylated genes in cancer stem cells were obtained
from Cui et al’ s study [1], in which they collected these genes from
three studies[25,26,27]. Twenty two of the 287 genes were found
on the CCA network.
Human signaling pathway and cellular signaling network
One hundred and eighty four human signaling pathways were
obtained from BioCarta (http://www.biocarta.com/) and a
human cellular signaling network was obtained from the study
of Cui et al.[1]. The human cellular signaling network included
1,634 nodes and 5,089 links, containing 2,403 activation
interactions, 741 repression interactions, 1,915 physical interac-
tions, and 30 links whose types are unknown (File S3).
Network of co-occurring and anti-co-occurring cancer
gene mutations
For any two genes, for example, A and B, the number of cancer
samples that sequenced both Gene A and Gene B was first
Figure 5. (A) Distribution of cancer gene mutations of the 22 cancer samples from Sjoblom et al. ’ study [7] in two modules of the
CCA network. The x axis represents the number (M) of samples that have at least one mutation in Module Two. The y axis represents the number
(N) of samples that have mutations only in Module Two. The red circle (pointed by a red arrow) indicates the real number of M and N. The heatmap
indicates the union distribution of the random number of M and N and its color represents the probability density. (B) Comparison of mutation
frequency for genes in Module One and genes in Module Two.
doi:10.1371/journal.pone.0013180.g005
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Genes A and B (AandB), that of cancer samples with mutations
only in Gene A (AnotB), that of cancer samples with mutations
only in Gene B (BnotA), and that of cancer samples with
mutations in neither Gene A nor gene B (notAnotB) were then
counted. The significance (P value) of co-occurring or anti-co-
occurring cancer gene mutations was further determined using
Fisher’s exact test based on the obtained four numbers. A network
of co-occurring and anti-co-occurring cancer gene mutations
(CCA network, File S1) was constructed by setting a P value cutoff
0.02. Any two genes with P value less than or equal to 0.02 (FDR
P,=0.08) were linked. Finally, a CCA network was constructed
from this method. The final network included 306 nodes and
1,366 links (Figure 1), which was drawn by pajek, a free network
visualization and analysis software (http://vlado.fmf.uni-lj.si/
pub/networks/pajek/).
The degree and CC value for each node in the CCA network
was calculated according to the formula presented by Barabasi and
Oltvai (File S4) [21]. The mutation frequency of cancer genes is
also given in File S4. The network components were identified by
a Java program designed for this purpose (File S5). The network
distance of two genes was obtained by calculating the length of
their shortest path, which was implemented using Dijkstra’s
algorithm. The degree distribution was calculated by R, a free
statistical software (http://cran.r-project.org/). As the CCA
network showed very clear modular structures, two network
modules (File S6) were manually identified without using other
tools.
Analysis of gene expression data
This study obtained the normalized human gene expression
profile across 79 human tissues from Su et al. ’ study [20] for the
analysis of gene expression similarity. The author extracted
expression profiles for genes included in the CCA network and
further measured the expression similarity of any two linked genes
in the CCA network by absolute Pearson’s correlation coefficient,
which is a frequently used metric in similar analysis [17].
Statistical computations
All statistical tests were performed using R software. The
randomization tests were performed by Java programs designed
for this purpose. The basic idea of the randomization tests was
introduced here by taking the test for the enrichment of co-
occurring mutations in human signaling pathways as an example.
Genes were first randomly re-connected in the network using the
same number of links. The number of re-generated links that are
within the same signaling pathways was then counted. These
procedures were repeated 5,000 times. The number of times (T)
the random number was greater than or equal to the real number
was counted. The P value was calculated using the formula (T+1)/
5001.
Supporting Information
File S1 The pajek network file of the network of cancer genes
with co-occurring and anti-co-occurring mutations
Found at: doi:10.1371/journal.pone.0013180.s001 (0.05 MB
TXT)
File S2 List of enriched molecular functions (MFs), biological
processes (BPs), and cellular components (CCs) of genes in module
1 and module 2.
Found at: doi:10.1371/journal.pone.0013180.s002 (0.05 MB
DOC)
File S3 List of the genes, their functions, cellular locations and
signaling relations in the human signaling network.
Found at: doi:10.1371/journal.pone.0013180.s003 (0.49 MB
XLS)
File S4 List of network nodes and their mutation frequency,
degree and clustering coefficient (CC).
Found at: doi:10.1371/journal.pone.0013180.s004 (0.01 MB
TXT)
File S5 The jave source code file for the identification of network
components.
Found at: doi:10.1371/journal.pone.0013180.s005 (0.00 MB
TXT)
File S6 List of genes in two network modules.
Found at: doi:10.1371/journal.pone.0013180.s006 (0.00 MB
TXT)
Figure S1 Degree distribution of the CCA network.
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